Composition and Method for Treating Neurological Disease (2005)
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,389,578 | Composition and Method for Treating Neurological Disease In force · High confidence UsedRemaining | Adamas Pharmaceuticals, Inc. | In force | High confidence | ||
| US 8,796,337 | Composition and Method for Treating Neurological Disease Term ended · USPTO later recorded non-payment Sep 7, 2026 Term ended Nov 23, 2025 · High confidence | Adamas Pharmaceuticals, Inc. | Term ended USPTO later recorded non-payment Sep 7, 2026 | Term ended Nov 23, 2025 | High confidence | |
| US 8,889,740 | Composition and Method for Treating Neurological Disease Term ended Ended no later than Nov 23, 2025 · Medium confidence | Adamas Pharmaceuticals, Inc. | Term ended | Ended no later than Nov 23, 2025 | Medium confidence | |
| US 8,895,614 | Composition and Method for Treating Neurological Disease Term ended Ended no later than Nov 23, 2025 · Medium confidence | Adamas Pharmaceuticals, Inc. | Term ended | Ended no later than Nov 23, 2025 | Medium confidence | |
| US 8,895,615 | Composition and Method for Treating Neurological Disease Term ended Ended no later than Nov 23, 2025 · Medium confidence | Adamas Pharmaceuticals, Inc. | Term ended | Ended no later than Nov 23, 2025 | Medium confidence | |
| US 8,895,616 | Composition and Method for Treating Neurological Disease Term ended Term ended Nov 23, 2025 · High confidence | Adamas Pharmaceuticals, Inc. | Term ended | Term ended Nov 23, 2025 | High confidence | |
| US 8,895,617 | Composition and Method for Treating Neurological Disease Term ended Ended no later than Nov 23, 2025 · Medium confidence | Adamas Pharmaceuticals, Inc. | Term ended | Ended no later than Nov 23, 2025 | Medium confidence | |
| US 8,895,618 | Composition and Method for Treating Neurological Disease Term ended Ended no later than Nov 23, 2025 · Low confidence | Adamas Pharmaceuticals, Inc. | Term ended | Ended no later than Nov 23, 2025 | Low confidence | |
| US 8,987,333 | Composition and Method for Treating Neurological Disease Term ended Ended no later than Nov 23, 2025 · Low confidence | Adamas Pharmaceuticals, Inc. | Term ended | Ended no later than Nov 23, 2025 | Low confidence | |
| US 9,072,697 | Composition and Method for Treating Neurological Disease Term ended Term ended Nov 23, 2025 · Low confidence | Adamas Pharmaceuticals, Inc. | Term ended | Term ended Nov 23, 2025 | Low confidence | |
| 9 more records in this group · Pro | ||||||
10 of 19 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 19, including 9 expired and 1 expiring within the 18 months from Nov 21, 2026.
1 of these is in force and held by Adamas Pharmaceuticals, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.